Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

[Image: see text] Background. Clinical course of the novel Coronavirus (SARS-CoV-2) Disease 2019 (COVID-19) is extremely heterogeneous, and infected individuals may be asymptomatic or develop acute respiratory manifestations. Elderly people and patients with pre-existing comorbidities, including mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifacio, Massimiliano, Binotto, Gianni, Tiribelli, Mario, Miggiano, Maria Cristina, Trawinska, Malgorzata Monika, Scaffidi, Luigi, Di Bona, Eros, Damiani, Daniela, Velotta, Vanessa, Ceccarelli, Giulia, Pierdomenico, Elisabetta, Loschirico, Mariella, Dubbini, Maria Vittoria, Cordioli, Maddalena, Ruggeri, Marco, Fanin, Renato, Semenzato, Gianpietro, Tacconelli, Evelina, Pizzolo, Giovanni, Krampera, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
632.Chronic Myeloid Leukemia: Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330233/
http://dx.doi.org/10.1182/blood-2020-140032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330233/
http://dx.doi.org/10.1182/blood-2020-140032

Ejemplares similares